June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Cytotoxicities of various ophthalmic antimicrobial solutions in SV40-immortalized human corneal epithelial cells
Author Affiliations & Notes
  • Jae Lim Chung
    Konyang University Kim's Eye Hospital, Seoul, Republic of Korea
  • Sang Wroul Song
    Konyang University Kim's Eye Hospital, Seoul, Republic of Korea
  • Byung Yeop Kim
    Konyang University Kim's Eye Hospital, Seoul, Republic of Korea
  • Joon Lee
    Myunggok Eye Research Institute, Konyang University, Seoul, Republic of Korea
  • Kyoung Yul Seo
    Shinchon Severance Hospital, Yonsei University, Seoul, Republic of Korea
  • Footnotes
    Commercial Relationships Jae Lim Chung, None; Sang Wroul Song, None; Byung Yeop Kim, None; Joon Lee, None; Kyoung Yul Seo, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 4287. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jae Lim Chung, Sang Wroul Song, Byung Yeop Kim, Joon Lee, Kyoung Yul Seo; Cytotoxicities of various ophthalmic antimicrobial solutions in SV40-immortalized human corneal epithelial cells. Invest. Ophthalmol. Vis. Sci. 2013;54(15):4287.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Currently high concentration ophthalmic antibiotics were introduced to increase the pharmacokinetic properties. However toxicity is a concern in using these agents. This study evaluated the cytotoxicities of various antibiotic eyedrops on SV40-immortalized human corneal epithelial cells by using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay.

Methods: Tested drugs were Cravit (levofloxacin 0.5%), Cravit 1.5 (levofloxacin 1.5%), Quixin (levofloxacin 0.5%, Benzalkonium chloride (BAK) 0.005%), Iquix (levofloxacin 1.5%), Vigamox (moxifloxacin 0.5%), Moxeza (moxifloxacin 0.5%, xanthan gum), Gatiflo (gatifloxacin 0.3%), Zymaxid (gatifloxacin 0.5%, BAK 0.005%), Besivance (besifloxacin, BAK 0.01%, durasite), Azasite (azithromycin 1%, BAK 0.003%, durasite), Tobrex (tobramycin 0.3%, BAK 0.01%) and standard powders of each drug. MTS assay was performed after 5~120 minutes of exposure to each solution.

Results: After the exposure to undiluted solutions cell viabilities were decreased to 9~73% from 5 minutes. At 30 minutes tobrex, zymaxid and quixin showed marked toxicity, Cravit 1.5, Iqux and Vigamox showed moderate toxicity and Cravit and Gatiflo showed mild toxicity. When exposed to 10 times diluted solutions, Tobrex, Besivance, Zymaxid, Quixin and Azasite, BAK containing products, showed moderate toxicity. After the exposure to standard powder, 0.6% besifloxacin, 0.5% gatifloxacin, 0.5% moxifloxacin, 1.5% levofloxacin and 0.5% levofloxacin showed toxicity results with decreased order. However 1% azithromycin and 0.3% tobramycin showed almost negative cytotoxicity.

Conclusions: High concentration drugs didn’t show increased cytotoxicity. The most important factor for the determination of cytotoxicity of antibiotic solutions was the concentration of BAK.

Keywords: 422 antibiotics/antifungals/antiparasitics • 573 keratitis • 513 endophthalmitis  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×